Roche: accelerated approval in lymphoma

(CercleFinance.com) - Roche announces that the US FDA has granted accelerated approval to its Polivy (polatuzumab vedotin-piiq ) in combination with bendamustine plus Rituxan (rituximab) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies.


The FDA's Accelerated Approval Program allows conditional approval of a medicine that fills an unmet medical need for a serious condition. Its durability depends on the verification of clinical benefits in a confirmation study.


Copyright (c) 2019 CercleFinance.com. All rights reserved.